Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
iRadimed Corp Market Cap
Based on ratings from 2 stock analysts, the iRadimed Corp stock price is expected to increase by 21.04% in 12 months. This is calculated by using the average 12-month stock price forecast for iRadimed Corp. The lowest target is $60 and the highest is $60. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assignedIRMD 1 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect iRadimed Corp to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on IRMD. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of IRMD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason Wittes Roth MKM | Buy | $60 | Maintains | Aug 2, 2024 |
| Jason Wittes Roth MKM | Buy | $65 | Reinstates | Apr 22, 2024 |
| Scott Henry Roth Capital | Buy | $36 | Maintains | Aug 2, 2021 |
Roth Capital | Buy | Upgrade | Jul 31, 2017 | |
Roth Capital | Neutral | Downgrade | Oct 5, 2016 | |
Roth Capital | Buy | $25 | Maintains | Apr 4, 2016 |
Roth Capital | Buy | $23 | Maintains | Jun 16, 2015 |
Roth Capital | Initiates | Aug 11, 2014 |
When did it IPO
2014
Staff Count
148
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Roger E. Susi
Market Cap
$627.7M
In 2023, IRMD generated $65.6M in revenue, which was a increase of 23.00% from the previous year. This can be seen as a signal that IRMD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Iradimed Corporation (NASDAQ: IRMD) will participate in the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference, highlighting its MRI-compatible medical devices.
Why It Matters - Iradimed's participation in a prominent growth conference signals potential investor interest and could enhance visibility, impacting stock performance and attracting new capital.
Sat, 03 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - IRadimed Corporation (NASDAQ: IRMD) held its Q2 2024 results conference call on August 1, 2024, featuring CEO Roger Susi and Controller Matt Garner.
Why It Matters - The timing of IRADIMED's Q2 2024 results conference call indicates upcoming insights into financial performance, which can influence stock valuation and investor sentiment.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - IRADIMED CORPORATION (NASDAQ: IRMD) reported its financial results for Q2 2024, continuing its role as a leader in MRI medical devices and the sole provider of non-magnetic IV infusion pumps and vital signs monitors.
Why It Matters - IRADIMED's financial results indicate its market position in MRI medical devices, signaling potential growth opportunities and risks that could impact stock performance.
Thu, 01 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - IRadimed (IRMD) reported Q3 earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.36 and up from $0.36 per share year-over-year.
Why It Matters - IRadimed's earnings beat expectations, indicating strong financial performance and growth. This positive trend may boost investor confidence and impact stock valuation.
Thu, 25 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Iradimed Corporation (NASDAQ: IRMD) will release its Q2 2024 financial results on August 1, 2024, before market open, followed by a conference call at 12:00 p.m. ET.
Why It Matters - Iradimed's upcoming financial results and conference call could significantly impact its stock price and investor sentiment, providing insights into performance and future expectations.
Fri, 07 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Iradimed Corporation (NASDAQ: IRMD) will uplist to the Nasdaq Global Market, starting June 14, 2024, continuing to trade under the ticker symbol “IRMD.”
Why It Matters - Iradimed's uplisting to the Nasdaq Global Market enhances visibility, potentially attracting institutional investors and increasing liquidity, which could positively impact stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
